Iconovo AB (ICO) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Flat results in Jun 25

NET SALES(HY) At SEK 0.59 MM has Grown at -69.52%
RAW MATERIAL COST(Y) Grown by 108.11% (YoY)
CASH AND EQV(HY) Lowest at SEK 43.1 MM

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 87 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.11

Return on Equity

-31.55%

Price to Book

0.66

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2025)

Net Profit:

-10 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-43.29%

6 Months

-13.73%

1 Year

-71.76%

2 Years

-84.56%

3 Years

-97.31%

4 Years

-98.19%

5 Years

-97.24%

Iconovo AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-30.92%

EBIT Growth (5y)

-152.08%

EBIT to Interest (avg)

-38.05

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.07

Sales to Capital Employed (avg)

0.04

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.76

EV to EBIT

-1.82

EV to EBITDA

-2.42

EV to Capital Employed

0.70

EV to Sales

49.15

PEG Ratio

Dividend Yield

ROCE (Latest)

-38.53%

ROE (Latest)

-31.22%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -50.00% vs -92.31% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -8.33% vs 26.72% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.20",
          "val2": "-7.50",
          "chgp": "-9.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.40",
          "val2": "-9.60",
          "chgp": "-8.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-84,401.60%",
          "val2": "-40,550.20%",
          "chgp": "-4,385.14%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -59.15% vs -58.48% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 10.46% vs 4.77% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.90",
          "val2": "7.10",
          "chgp": "-59.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-30.50",
          "val2": "-43.70",
          "chgp": "30.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.50",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-41.10",
          "val2": "-45.90",
          "chgp": "10.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-14,061.00%",
          "val2": "-7,602.20%",
          "chgp": "-645.88%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.10

0.20

-50.00%

Operating Profit (PBDIT) excl Other Income

-8.20

-7.50

-9.33%

Interest

0.10

Exceptional Items

0.00

Consolidate Net Profit

-10.40

-9.60

-8.33%

Operating Profit Margin (Excl OI)

-84,401.60%

-40,550.20%

-4,385.14%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is -50.00% vs -92.31% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -8.33% vs 26.72% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

2.90

7.10

-59.15%

Operating Profit (PBDIT) excl Other Income

-30.50

-43.70

30.21%

Interest

0.50

Exceptional Items

0.00

Consolidate Net Profit

-41.10

-45.90

10.46%

Operating Profit Margin (Excl OI)

-14,061.00%

-7,602.20%

-645.88%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -59.15% vs -58.48% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 10.46% vs 4.77% in Dec 2023

All Annual Results

Company CV

About Iconovo AB

Iconovo AB

Pharmaceuticals & Biotechnology

Iconovo AB is a Sweden-based company, which offers inhalation solutions for pharmaceutical companies. Solutions are based on the Company’s device platforms and include formulation, analytical testing and documentation. Iconovo Ab develops products, which are a part of device family and include: ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices and ICOpre, pre-metered devices. Moreover, the Company offers programs, which include development of generic inhalation products, where the products are registered based on therapeutic equivalence; development of inhalation products based on a generic application programming interface (API) and new chemical entity (NCE); as well as phase I-II clinical trials using ICOone.

Company Coordinates

Company Details

Medicon Village, Scheelevagen 2 , LUND None : 223 81

Tel: 46 46 2756777

https://iconovo.se/

Registrar Details